Objective: The mortality rate of non-small cell lung cancer ranks first worldwide. The lack of effective and accurate diagnosis contributes to the unfavorable prognosis of non-small cell lung cancer patients since most of them are diagnosed at an advanced stage. In the present study, we aimed to investigate whether LncRNA SNHG4 was implicated in predicting non-small cell lung cancer diagnosis and outcomes.

Methods: We collected 68 unpaired serums and tissues from patients with non-small cell lung cancer and from healthy volunteers. Quantitative real-time polymerase chain reaction (qRT-PCR) assays were conducted accordingly. Furthermore, we uncovered the correlation of their expressions with clinicopathological features and the diagnostic values. The five-year survival rate and disease-free rate were analyzed using Kaplan-Meier methods. Finally, experiments were performed to explore the role and mechanisms of LncRNA SNHG4 in non-small cell lung cancer.

Results: LncRNA SNHG4 level was significantly more elevated in non-small cell lung cancer serum samples and tissues than in healthy controls (<0.01). A receiver operating characteristic (ROC) assay demonstrated that the areas under the curve (AUC) were 0.9087 (95% CI, 0.8529 to 0.9646; specificity=98.53%, sensitivity=80.88%, cutoff=1.7941) and 0.9457 (95% CI, 0.8994 to 0.9920; specificity=100.00%, sensitivity=82.80%, cutoff=1.828), separately. Notably, a higher expression of LncRNA SNHG4 was positively correlated with the clinical stage, lymph node metastasis, and smoking. Meanwhile, patients with higher expressions of LncRNA SNHG4 had significantly lower overall survival rates and disease-free rates. In the experiments, we found that LncRNA SNHG4 was strongly elevated in the non-small cell lines compared with the human normal lung epithelial cell line BEAS-2B. After transfection with the SNHG4 silencing plasmid, A549 cell viability was significantly inhibited, while apoptosis was promoted.

Conclusion: LncRNA SNHG4 might have diagnostic and prognostic significance in non-small cell lung cancer. However, it is imperative to conduct further experiments on the aspect of the biological mechanisms of LncRNA SNHG4 in the occurrence and development of non-small cell lung cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

non-small cell
28
cell lung
28
lung cancer
24
lncrna snhg4
12
non-small
7
cell
7
lung
7
cancer
6
long non-coding
4
non-coding rna
4

Similar Publications

Objectives: Immune checkpoint inhibitor (ICI)-containing treatment is currently prescribed as first-line treatment for all patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, only 30-45% of patients show no progression within 12 months after treatment start. Various biomarkers are being studied to save costly and potentially harmful treatment in non-responders.

View Article and Find Full Text PDF

Objectives: Chest wall infiltration in primary lung cancer affects the surgical and therapeutic strategies. This study evaluates the efficacy of the chest wall vessel involvement in subpleural lung cancer (CWVI) on ultra-high-resolution CT (UHR-CT) for detecting chest wall invasion.

Materials And Methods: A retrospective analysis of lung cancer cases with confirmed pleural and chest wall invasion was conducted from November 2019 to April 2022.

View Article and Find Full Text PDF

Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer.

Commun Biol

January 2025

Department of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Hyperactive c-Met signaling pathway caused by altered MET is a common mechanism underlying gastric cancer and represents an attractive target for the treatment of gastric cancer with MET alterations. However, no c-Met kinase inhibitors are currently approved specifically for the treatment of c-Met-amplified gastric cancer. Recently, bozitinib, a highly selective c-Met kinase inhibitor, has shown remarkable potency in selectively inhibiting MET-altered non-small cell lung cancer and secondary glioblastoma.

View Article and Find Full Text PDF

Association between airway microbiota and systemic inflammation markers in non-small cell lung cancer patients.

Sci Rep

January 2025

Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

Growing evidences have suggested the airway microbiota may participate in lung cancer progression. However, little was known about the relationship between airway microbiota and lung cancer associated systemic inflammation. Here we aimed to explore the association between sputum microbiota and systemic inflammation in lung cancer.

View Article and Find Full Text PDF

Design, Structure Optimization, and Preclinical Characterization of JAB-21822, a Covalent Inhibitor of KRAS.

J Med Chem

January 2025

Chief executive officer, Jacobio Pharmaceuticals Group Co., Ltd., Beijing100176, P. R. China.

KRAS is the most frequently mutated driver oncogene in human cancer, and KRAS mutation is commonly found in non-small-cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC). Inhibitors that covalently modify the mutated codon 12 cysteine have completed proof-of-concept studies in the clinic. Here, we describe structure-based design and cocrystal-aided drug optimization of a series of compounds with the 1,8-naphthyridine-3-carbonitrile scaffold.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!